Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.

Obstet Gynecol Sci · 2020 · PMC7494761 · PMID 32872764

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP=0.07so close (0.05 < p ≤ 0.1)

After a median follow-up of 3.8 (range, 0–11.5) years, patients with BRCA1/2 -mutated tumors showed a trend toward improved PFI and PFS as compared to those with BRCA1/2 -intact tumors (median survival: 17 vs. 6 months [HR, 0.48; 95% CI, 0.22–1.06; P=0.07] and 20 vs. 11 months [HR, 0.53; 95% CI, 0.26–1.09; P=0.08], respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.